BCM
KALV

BlueCrest Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

BlueCrest Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,620
Closed -$304K – 750
2019
Q1 		$304K Buy
+10,620
New +$230K 0.01% 702

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlueCrest Capital Management's KALV Position: Q2 2019 in Review

BlueCrest Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2019, closing a stake of 10,620 shares — an estimated $304K sold.

BlueCrest Capital Management first reported a position in KALV in Q1 2019 and held it in 1 quarter. The position peaked at $304K in Q1 2019. 75 funds tracked by Wall St. Rank hold KALV as of Q2 2019.

  • BlueCrest Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 10,620 KalVista Pharmaceuticals shares in Q2 2019, an estimated $304K.
  • BlueCrest Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's KalVista Pharmaceuticals position peaked at $304K in Q1 2019.
  • 75 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.